Role of Insulin Resistance in the Development of Nonalcoholic Fatty Liver Disease in People With Type 2 Diabetes: From Bench to Patient Care.
Juan Patricio NogueiraKenneth CusiPublished in: Diabetes spectrum : a publication of the American Diabetes Association (2024)
Insulin resistance is implicated in both the pathogenesis of nonalcoholic fatty liver disease (NAFLD) and its progression from steatosis to steatohepatitis, cirrhosis, and even hepatocellular carcinoma, which is known to be more common in people with type 2 diabetes. This article reviews the role of insulin resistance in the metabolic dysfunction observed in obesity, type 2 diabetes, atherogenic dyslipidemia, and hypertension and how it is a driver of the natural history of NAFLD by promoting glucotoxicity and lipotoxicity. The authors also review the genetic and environmental factors that stimulate steatohepatitis and fibrosis progression and their relationship with cardiovascular disease and summarize guidelines supporting the treatment of NAFLD with diabetes medications that reduce insulin resistance, such as pioglitazone or glucagon-like peptide 1 receptor agonists.
Keyphrases
- insulin resistance
- type diabetes
- cardiovascular disease
- liver fibrosis
- glycemic control
- high fat diet induced
- high fat diet
- metabolic syndrome
- adipose tissue
- polycystic ovary syndrome
- skeletal muscle
- blood pressure
- oxidative stress
- clinical practice
- genome wide
- cardiovascular risk factors
- dna methylation
- copy number
- body mass index
- coronary artery disease
- gene expression
- combination therapy